{ "ok": true, "cik": "1400118", "ticker": "SGMT", "name": "Sagimet Biosciences Inc.", "filings": [ { "form": "8-K", "filed": "2026-10-01", "items": [ "1.01 Entry into a Material Definitive Agreement", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1400118/000119312526409335/0001193125-26-409335-index.htm" }, { "form": "8-K", "filed": "2026-09-30", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/0001193125-26-408224-index.htm" }, { "form": "8-K", "filed": "2026-08-13", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1400118/000119312526347854/0001193125-26-347854-index.htm" }, { "form": "8-K", "filed": "2026-08-11", "items": [ "2.02 Results of Operations and Financial Condition", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/0001193125-26-343446-index.htm" }, { "form": "10-Q", "filed": "2026-08-11", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1400118/000119312526343441/0001193125-26-343441-index.htm" }, { "form": "8-K", "filed": "2026-07-21", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1400118/000119312526309334/0001193125-26-309334-index.htm" } ], "events12m": 18, "healthWatch": { "window": "last 12 months", "since": "2025-10-02", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 3, "latest": { "filed": "2026-06-12", "url": "https://www.sec.gov/Archives/edgar/data/1400118/000110465926073431/0001104659-26-073431-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001400118.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1400118" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up Sagimet Biosciences Inc. ($SGMT). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-10-01. 18 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-08-22.", "auditor": { "changes": [ { "filed": "2025-08-22", "url": "https://www.sec.gov/Archives/edgar/data/1400118/000110465925081630/0001104659-25-081630-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2023-12-31", "revenue": 2000000, "revenueGrowth1y": null, "revenueGrowthPerYear": null, "yearsOfData": 1, "operatingMargin": -15.37, "operatingMarginPrior": null, "netMargin": -13.938, "operatingCashFlow": -23766000, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": 19777000, "researchShareOfRevenue": 9.8885, "cash": 75139000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2023-12-31", "revenue": 2000000 } ], "totalEquity": 91065000, "totalAssets": 96719000, "equityRatio": 0.9415419927832174, "returnOnEquity": -0.30611101960138365, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "latestAudited": { "fiscalYearEnd": "2025-12-31", "revenue": null, "operatingCashFlow": -45650000, "cash": 35021000, "totalEquity": 111381000, "totalAssets": 116482000, "equityRatio": 0.956207826101887 }, "revenueYearIsOld": true, "earningsPerShare": -2.66, "sharesOutstanding": 10460335, "bookValuePerShare": 8.705744127697631, "revenuePerShare": 0.19119846544111638, "range80": null, "ifPaceHeld": null }, "edgarette": "🔖 Exposure: revenue $2.0M (FY2023). Experience: one year on record; operating margin -1537.0%. Soundness: equity 94.2% of assets, return on equity -30.6%. Credibility: one audited year, little weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1537.0% against a -3.8% median.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Sagimet Biosciences (SGMT) reported revenue of $2 million in FY2023, operating margin -1537% against a -3.8% median for pharmaceutical preparations, equity 94.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Sagimet Biosciences Inc. against its own record and its peers
Operating marginPeer median -3.8%-1537.0%Equity of assetsPeer median 40.3%94.2%Return on equityPeer median -1.1%-30.6%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Sagimet Biosciences (SGMT) reported revenue of $2 million in FY2023, operating margin -1537% against a -3.8% median for pharmaceutical preparations, equity 94.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2023-12-31", "revenue": 2000000, "totalDebt": null, "cash": 75139000 }, "experience": { "revenueGrowth1y": null, "revenueGrowthPerYear": null, "operatingMargin": -15.37, "operatingMarginPrior": null, "netMargin": -13.938, "freeCashFlow": null }, "soundness": { "equityRatio": 0.9415419927832174, "returnOnEquity": -0.30611101960138365, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 1, "weight": "little", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2025-08-22", "url": "https://www.sec.gov/Archives/edgar/data/1400118/000110465925081630/0001104659-25-081630-index.htm" } }, "healthWatch": { "window": "last 12 months", "since": "2025-10-02", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 3, "latest": { "filed": "2026-06-12", "url": "https://www.sec.gov/Archives/edgar/data/1400118/000110465926073431/0001104659-26-073431-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": null, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001400118.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1400118" }, "speedCash": null, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative (-$45.6M in FY2025)" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2023-12-31", "operating": -23766000, "investing": 12580000, "financing": 86167000, "capitalSpending": null, "free": null, "trend": [ { "fiscalYearEnd": "2023-12-31", "operating": -23766000, "free": null } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2023-12-31", "cash": 75139000, "shortTerm": 19758000, "longTerm": null, "equityHoldings": null, "totalAssets": 96719000, "ladder": null, "currentRatio": 17.09, "unrealizedGain": 30000, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": null, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative (-$45.6M in FY2025)" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2023-12-31", "operating": -23766000, "investing": 12580000, "financing": 86167000, "capitalSpending": null, "free": null, "trend": [ { "fiscalYearEnd": "2023-12-31", "operating": -23766000, "free": null } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2023-12-31", "cash": 75139000, "shortTerm": 19758000, "longTerm": null, "equityHoldings": null, "totalAssets": 96719000, "ladder": null, "currentRatio": 17.09, "unrealizedGain": 30000, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }